OTCMKTS:MAYNF Mayne Pharma Group (MAYNF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MAYNF Stock Alerts $4.54 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$4.54▼$4.5450-Day Range$3.55▼$4.5952-Week Range$1.90▼$4.59Volume50 shsAverage Volume1,346 shsMarket CapitalizationN/AP/E Ratio126.11Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Mayne Pharma Group alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Mayne Pharma Group Stock (OTCMKTS:MAYNF)Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.Read More MAYNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAYNF Stock News HeadlinesApril 23, 2024 | afr.comMayne Pharma Group LimitedApril 23, 2024 | americanbankingnews.comMayne Pharma Group (OTCMKTS:MAYNF) Trading Up 1.6%April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 28, 2024 | seekingalpha.comMayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comMayne Pharma Group Limited (MAYNF)February 27, 2024 | msn.comMayne Pharma Group reports 1H resultsDecember 29, 2023 | finance.yahoo.comMayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Mayne Pharma Group (OtherMAYNF) and Biogen (BIIB)April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.November 18, 2023 | finance.yahoo.comWhile institutions invested in Mayne Pharma Group Limited (ASX:MYX) benefited from last week's 12% gain, retail investors stood to gain the mostOctober 28, 2023 | finance.yahoo.comShawn O’Brien Buys Handful Of Shares In Mayne Pharma GroupOctober 23, 2023 | finance.yahoo.comStrong week for Mayne Pharma Group (ASX:MYX) shareholders doesn't alleviate pain of five-year lossSeptember 1, 2023 | finance.yahoo.comMayne Pharma Group Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagJune 13, 2023 | markets.businessinsider.comWilsons Sticks to Its Buy Rating for Mayne Pharma Group (MAYNF)May 16, 2023 | afr.comInfomedia wrangler Viburnum butts heads with Mayne Pharma’s boardApril 18, 2023 | finance.yahoo.comThere's No Escaping Mayne Pharma Group Limited's (ASX:MYX) Muted RevenuesMarch 1, 2023 | finance.yahoo.comMayne Pharma Group Limited (ASX:MYX) Shares Could Be 49% Below Their Intrinsic Value EstimateFebruary 27, 2023 | finance.yahoo.comDr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription DealFebruary 27, 2023 | msn.comDr Reddy's Laboratories announces agreement to acquire Mayne Pharma’s U.S. generic prescription product portfolioFebruary 27, 2023 | msn.comDr. Reddy’s Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolioJanuary 31, 2023 | seekingalpha.comMAYND Mayne Pharma Group LimitedDecember 7, 2022 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lantheus (LNTH) and Mayne Pharma Group Limited (OtherMAYNF)December 5, 2022 | seekingalpha.comTherapeuticsMD enters agreements to license products to Mayne PharmaDecember 2, 2022 | finance.yahoo.comMayne Pharma Group Limited (ASX:MYX) Analysts Just Trimmed Their Revenue Forecasts By 19%November 9, 2022 | finance.yahoo.comMayne Pharma Group (ASX:MYX) investors are sitting on a loss of 54% if they invested five years agoSeptember 13, 2022 | fool.com.auIs the Mayne Pharma Group Ltd share price in the buy zone after today’s news?August 31, 2022 | finance.yahoo.comAnalysts Are More Bearish On Mayne Pharma Group Limited (ASX:MYX) Than They Used To BeSee More Headlines Receive MAYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:MAYNF CUSIPN/A CIKN/A Webwww.maynepharma.com Phone(188) 209-2666FaxN/AEmployees780Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio126.11 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Shawn Patrick O'Brien B.Sc (Age 65)CEO, MD & Director Comp: $829.28kMr. Aaron GrayChief Financial OfficerMs. Kimberly Parker J.D.Executive VP & General CounselMr. Brant Schofield (Age 58)Executive Vice President of Corporate Development Comp: $678.35kMs. Erinn NathanielDirector of Global Human ResourcesMr. Daniel MooreExecutive Vice President of CommercialDr. Frank Casty M.D.Executive VP & Global Chief Medical OfficerMr. Brenton WalterFinancial ControllerMs. Laura LoftusAssociate General Counsel & Company SecretaryMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All Competitors MAYNF Stock Analysis - Frequently Asked Questions How have MAYNF shares performed in 2024? Mayne Pharma Group's stock was trading at $4.25 on January 1st, 2024. Since then, MAYNF stock has increased by 6.8% and is now trading at $4.54. View the best growth stocks for 2024 here. When did Mayne Pharma Group's stock split? Mayne Pharma Group shares reverse split before market open on Wednesday, January 18th 2023. The 1-20 reverse split was announced on Wednesday, January 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Mayne Pharma Group? Shares of MAYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MAYNF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mayne Pharma Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
